These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 29720090)
1. Sulphite oxidase (SO) - a mitochondrial autoantigen as target for humoral and cellular immune reactions in primary sclerosing cholangitis. Preuß BE; Berg CP; Werner C; Plankenhorn S; Malek NP; Klein R BMC Gastroenterol; 2018 May; 18(1):58. PubMed ID: 29720090 [TBL] [Abstract][Full Text] [Related]
2. Demonstration of autoantibodies to recombinant human sulphite oxidase in patients with chronic liver disorders and analysis of their clinical relevance. Preuss B; Berg C; Altenberend F; Gregor M; Stevanovic S; Klein R Clin Exp Immunol; 2007 Nov; 150(2):312-21. PubMed ID: 17711488 [TBL] [Abstract][Full Text] [Related]
3. Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis? van Milligen de Wit AW; Kuiper H; Camoglio L; van Bracht J; Jones EA; Tytgat GN; van Deventer SJ Eur J Gastroenterol Hepatol; 1999 Feb; 11(2):129-36. PubMed ID: 10102223 [TBL] [Abstract][Full Text] [Related]
4. Phenotyping and auto-antibody production by liver-infiltrating B cells in primary sclerosing cholangitis and primary biliary cholangitis. Chung BK; Guevel BT; Reynolds GM; Gupta Udatha DB; Henriksen EK; Stamataki Z; Hirschfield GM; Karlsen TH; Liaskou E J Autoimmun; 2017 Feb; 77():45-54. PubMed ID: 27784538 [TBL] [Abstract][Full Text] [Related]
5. Autoantibodies to glutathione S-transferase theta 1 in patients with primary sclerosing cholangitis and other autoimmune diseases. Ardesjö B; Hansson CM; Bruder CE; Rorsman F; Betterle C; Dumanski JP; Kämpe O; Ekwall O J Autoimmun; 2008 Jun; 30(4):273-82. PubMed ID: 18242955 [TBL] [Abstract][Full Text] [Related]
6. Identification and characterization of autoantibodies against catalase and alpha-enolase in patients with primary sclerosing cholangitis. Orth T; Kellner R; Diekmann O; Faust J; Meyer zum Büschenfelde KH; Mayet WJ Clin Exp Immunol; 1998 Jun; 112(3):507-15. PubMed ID: 9649223 [TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2 Meng F; Kennedy L; Hargrove L; Demieville J; Jones H; Madeka T; Karstens A; Chappell K; Alpini G; Sybenga A; Invernizzi P; Bernuzzi F; DeMorrow S; Francis H Lab Invest; 2018 Nov; 98(11):1465-1477. PubMed ID: 30143751 [TBL] [Abstract][Full Text] [Related]
8. Primary sclerosing cholangitis is associated with autoreactive IgA antibodies against biliary epithelial cells. Berglin L; Björkström NK; Bergquist A Scand J Gastroenterol; 2013 Jun; 48(6):719-28. PubMed ID: 23713804 [TBL] [Abstract][Full Text] [Related]
9. Case report: anti-proteinase 3 antibody activity in a patient with primary sclerosing cholangitis: clinical remission following ursodeoxycholic acid therapy. Wong SS; Lawton JW J Gastroenterol Hepatol; 1996 Dec; 11(12):1161-3. PubMed ID: 9034936 [TBL] [Abstract][Full Text] [Related]
10. [Primary sclerosing cholangitis (PSC)--humoral immune phenomena, pathogenetic aspects and therapeutic possibilities]. Hopf U; Stemerowicz R; Knigge O; Khadar R; König V; Lobeck H; Neuhaus P Z Gastroenterol; 1993 Feb; 31 Suppl 2():106-10. PubMed ID: 7483687 [TBL] [Abstract][Full Text] [Related]
11. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. van Hoogstraten HJ; Vleggaar FP; Boland GJ; van Steenbergen W; Griffioen P; Hop WC; van Hattum J; van Berge Henegouwen GP; Schalm SW; van Buuren HR Am J Gastroenterol; 2000 Aug; 95(8):2015-22. PubMed ID: 10950051 [TBL] [Abstract][Full Text] [Related]
12. Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis. Zen Y; Fujii T; Harada K; Kawano M; Yamada K; Takahira M; Nakanuma Y Hepatology; 2007 Jun; 45(6):1538-46. PubMed ID: 17518371 [TBL] [Abstract][Full Text] [Related]
14. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Pardi DS; Loftus EV; Kremers WK; Keach J; Lindor KD Gastroenterology; 2003 Apr; 124(4):889-93. PubMed ID: 12671884 [TBL] [Abstract][Full Text] [Related]
15. Autoantibodies in sclerosing cholangitis against a shared peptide in biliary and colon epithelium. Mandal A; Dasgupta A; Jeffers L; Squillante L; Hyder S; Reddy R; Schiff E; Das KM Gastroenterology; 1994 Jan; 106(1):185-92. PubMed ID: 7506217 [TBL] [Abstract][Full Text] [Related]
16. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Sabino J; Vieira-Silva S; Machiels K; Joossens M; Falony G; Ballet V; Ferrante M; Van Assche G; Van der Merwe S; Vermeire S; Raes J Gut; 2016 Oct; 65(10):1681-9. PubMed ID: 27207975 [TBL] [Abstract][Full Text] [Related]
17. Novel developments in IBD-related sclerosing cholangitis. Ponsioen CY Best Pract Res Clin Gastroenterol; 2011 Apr; 25 Suppl 1():S15-8. PubMed ID: 21640925 [TBL] [Abstract][Full Text] [Related]
18. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Lindström L; Hultcrantz R; Boberg KM; Friis-Liby I; Bergquist A Clin Gastroenterol Hepatol; 2013 Jul; 11(7):841-6. PubMed ID: 23353641 [TBL] [Abstract][Full Text] [Related]
19. Autoantibody profile of primary sclerosing cholangitis. Gur H; Shen G; Sutjita M; Terrberry J; Alosachie I; Barka N; Lin HC; Peter JB; Meroni PL; Kaplan M Pathobiology; 1995; 63(2):76-82. PubMed ID: 8554703 [TBL] [Abstract][Full Text] [Related]